Table 2.
SVD progression during 7-year follow-up (n = 100).
| Variables | Baseline | Follow-up | Change | p |
|---|---|---|---|---|
| WMH volume, ml, median (IQR) | 3.86 (2.06–7.31) | 7.34 (3.64–12.50) | 2.72 (0.68–5.51) | <0.001 |
| PWMH volume, ml, median (IQR) | 1.56 (0.77–3.09) | 3.38 (2.06–5.73) | 1.75 (0.74–3.66) | <0.001 |
| DWMH volume, ml, median (IQR) | 2.29 (1.14–4.67) | 2.94 (1.43–6.02) | 0.14 (−0.82 to 1.77) | 0.053 |
| ⩾1 Lacune, n (%) | 9 (9.00) | 14 (14.00) | 7 (7.00) a | 0.063 |
| ⩾1 CMB, n (%) | 9 (9.00) | 26 (26.00) | 22 (22.00) a | <0.001 |
| Extensive BG-ePVS, n (%) | 7 (7.00) | 16 (16.00) | 20 (20.00) a | 0.004 |
| Extensive CS-ePVS, n (%) | 5 (5.00) | 20 (20.00) | 36 (36.00) a | <0.001 |
| SVD score ⩾2, n (%) | 8 (8.00) | 22 (22.00) | 19 (19.00) a | <0.001 |
a
Numbers and percentages of participants with progression of respective SVD markers.
BG, basal ganglia; CMB, cerebral microbleed; CS, centrum semiovale; DWMH, deep white matter hyperintensity; ePVS, enlarged perivascular spaces; IQR, interquartile range; PWMH, periventricular white matter hyperintensities; SVD, cerebral small vessel disease; WMH, white matter hyperintensities.